HepaAiQ model resulted in a sensitivity of 70.8% (95% CI: 59.7%−81.8%) in early‐stage HCC and a specificity of 89.5% (95% CI: 84.1%−94.9%) in CHB/LC (Table 2), compared to a sensitivity of 58.5% (95% CI: 46.5%−70.4%) and a specificity of 92.7% (95% CI: 87.9%−97.6%) by AFP in the same set (Table S7). Here, AFP is linked to hepatocellular carcinoma.